Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 7/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26065191 | 0.86 | TAAR1 (0.59) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL29633122 | 0.86 | CYP1A2 (0.61) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL14655685 | 0.86 | CYP1A2 (0.61) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL23753586 | 0.84 | CYP1A2 (0.59) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6030030 | 0.84 | CYP1A2 (0.59) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL26065193 | 0.82 | TAAR1 (0.54) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL26065194 | 0.82 | TAAR1 (0.54) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL26065197 | 0.81 | TAAR1 (0.56) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL26065187 | 0.81 | TAAR1 (0.53) | TAAR1CYP1A2HTR2AHTR2CHTR2B | |
| SCHEMBL23360636 | 0.80 | CYP1A2 (0.54) | TAAR1CYP1A2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | TAAR1 66/4885CYP1A2 753/4885HTR2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.